{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:41:09Z","timestamp":1792654869288,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA199092"],"award-info":[{"award-number":["U54 CA199092"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA248493"],"award-info":[{"award-number":["R01 CA248493"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 EB021048"],"award-info":[{"award-number":["R01 EB021048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00259-020-05097-y","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T20:02:36Z","timestamp":1605124956000},"page":"1302-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma"],"prefix":"10.1007","volume":"48","author":[{"given":"Anchal","family":"Ghai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zheleznyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Mixdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"O\u2019Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ritchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Shokeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3133-6717","authenticated-orcid":false,"given":"Samuel","family":"Achilefu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"issue":"2","key":"5097_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/jnumed.117.196063","volume":"59","author":"A Ghai","year":"2018","unstructured":"Ghai A, et al. Preclinical development of CD38-targeted [(89)Zr]Zr-DFO-daratumumab for imaging multiple myeloma. J Nucl Med. 2018;59(2):216\u201322.","journal-title":"J Nucl Med"},{"issue":"9686","key":"5097_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab MS, et al. Multiple myeloma. Lancet. 2009;374(9686):324\u201339.","journal-title":"Lancet"},{"issue":"8","key":"5097_CR3","first-page":"1637","volume":"7","author":"JD Malaer","year":"2017","unstructured":"Malaer JD, Mathew PA. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. Am J Cancer Res. 2017;7(8):1637\u201341.","journal-title":"Am J Cancer Res"},{"key":"5097_CR4","unstructured":"National Cancer Institute. Cancer stat facts: myeloma. June 11, 2020]; Available from: http:\/\/mdanderson.libanswers.com\/faq\/26219."},{"key":"5097_CR5","doi-asserted-by":"publisher","first-page":"6084012","DOI":"10.1155\/2019\/6084012","volume":"2019","author":"H Nishida","year":"2019","unstructured":"Nishida H, Yamada T. Monoclonal antibody therapies in multiple myeloma: a challenge to develop novel targets. J Oncol. 2019;2019:6084012.","journal-title":"J Oncol"},{"issue":"9","key":"5097_CR6","first-page":"599","volume":"13","author":"P Sondergeld","year":"2015","unstructured":"Sondergeld P, et al. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13(9):599\u2013609.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"5097_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","volume":"9","author":"Y Wang","year":"2016","unstructured":"Wang Y, et al. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):55.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"5097_CR8","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi ED, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775\u201384.","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"5097_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","volume":"39","author":"PR Kumaresan","year":"2002","unstructured":"Kumaresan PR, et al. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39(1\u20132):1\u20138.","journal-title":"Mol Immunol"},{"issue":"3\u20134","key":"5097_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s002510000274","volume":"52","author":"KS Boles","year":"2001","unstructured":"Boles KS, Mathew PA. Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics. 2001;52(3\u20134):302\u20137.","journal-title":"Immunogenetics"},{"issue":"10","key":"5097_CR11","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.4049\/jimmunol.167.10.5517","volume":"167","author":"A Bouchon","year":"2001","unstructured":"Bouchon A, et al. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol. 2001;167(10):5517\u201321.","journal-title":"J Immunol"},{"issue":"18","key":"5097_CR12","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1182\/blood-2008-10-183772","volume":"113","author":"YT Tai","year":"2009","unstructured":"Tai YT, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009;113(18):4309\u201318.","journal-title":"Blood"},{"issue":"7","key":"5097_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"issue":"3","key":"5097_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","volume":"120","author":"JA Zonder","year":"2012","unstructured":"Zonder JA, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552\u20139.","journal-title":"Blood"},{"issue":"13","key":"5097_CR15","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1182\/blood-2016-05-636357","volume":"128","author":"V Hoyos","year":"2016","unstructured":"Hoyos V, Borrello I. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood. 2016;128(13):1679\u201387.","journal-title":"Blood"},{"issue":"3","key":"5097_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11307-017-1069-7","volume":"19","author":"V Ponomarev","year":"2017","unstructured":"Ponomarev V. Advancing immune and cell-based therapies through imaging. Mol Imaging Biol. 2017;19(3):379\u201384.","journal-title":"Mol Imaging Biol"},{"issue":"5","key":"5097_CR17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","volume":"159","author":"E Zamagni","year":"2012","unstructured":"Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159(5):499\u2013513.","journal-title":"Br J Haematol"},{"issue":"1","key":"5097_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2967\/jnumed.115.163808","volume":"57","author":"R Vij","year":"2016","unstructured":"Vij R, Fowler KJ, Shokeen M. New approaches to molecular imaging of multiple myeloma. J Nucl Med. 2016;57(1):1\u20134.","journal-title":"J Nucl Med"},{"issue":"23","key":"5097_CR19","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989\u201395.","journal-title":"Blood"},{"issue":"10","key":"5097_CR20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2967\/jnumed.116.177493","volume":"57","author":"EB Ehlerding","year":"2016","unstructured":"Ehlerding EB, et al. Molecular imaging of immunotherapy targets in cancer. J Nucl Med. 2016;57(10):1487\u201392.","journal-title":"J Nucl Med"},{"issue":"11","key":"5097_CR21","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.2967\/jnumed.109.065862","volume":"50","author":"PK Borjesson","year":"2009","unstructured":"Borjesson PK, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50(11):1828\u201336.","journal-title":"J Nucl Med"},{"issue":"15","key":"5097_CR22","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1158\/1078-0432.CCR-14-0491","volume":"20","author":"SB Gaykema","year":"2014","unstructured":"Gaykema SB, et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014;20(15):3945\u201354.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5097_CR23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","volume":"45","author":"L Kang","year":"2018","unstructured":"Kang L, et al. ImmunoPET imaging of CD38 in murine lymphoma models using (89)Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018;45(8):1372\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5097_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s41048-016-0016-5","volume":"1","author":"C Dong","year":"2015","unstructured":"Dong C, Liu Z, Wang F. Radioligand saturation binding for quantitative analysis of ligand-receptor interactions. Biophys Rep. 2015;1:148\u201355.","journal-title":"Biophys Rep"},{"key":"5097_CR25","unstructured":"Center for Drug Evaluation and Research, Pharmacology Reviews. 2015."},{"issue":"4","key":"5097_CR26","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329\u201337.","journal-title":"Blood"},{"issue":"1","key":"5097_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","volume":"88","author":"A Veillette","year":"2013","unstructured":"Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88(1):168\u201377.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"5097_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"5097_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjh.15384","volume":"182","author":"S Jagannath","year":"2018","unstructured":"Jagannath S, et al. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018;182(4):495\u2013503.","journal-title":"Br J Haematol"},{"key":"5097_CR30","doi-asserted-by":"crossref","unstructured":"Campbell KS, Cohen AD, Pazina T. Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody. Elotuzumab in Multiple Myeloma Front Immunol. 2018;9:2551.","DOI":"10.3389\/fimmu.2018.02551"},{"issue":"10","key":"5097_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.humimm.2009.07.004","volume":"70","author":"M Bernal","year":"2009","unstructured":"Bernal M, et al. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol. 2009;70(10):854\u20137.","journal-title":"Hum Immunol"},{"key":"5097_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.49","volume":"5","author":"T Dosani","year":"2015","unstructured":"Dosani T, et al. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 2015;5:e321.","journal-title":"Blood Cancer J"},{"issue":"10135","key":"5097_CR33","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pages","year":"2018","unstructured":"Pages F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128\u201339.","journal-title":"Lancet"},{"key":"5097_CR34","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.2147\/DDDT.S87561","volume":"9","author":"RL Van Heertum","year":"2015","unstructured":"Van Heertum RL, et al. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Des Devel Ther. 2015;9:5215\u201323.","journal-title":"Drug Des Devel Ther"},{"key":"5097_CR35","doi-asserted-by":"crossref","unstructured":"Ulaner, G.A., et al., CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging. Radiology, 2020: p. 192621.","DOI":"10.1148\/radiol.2020192621"},{"key":"5097_CR36","doi-asserted-by":"crossref","unstructured":"Zeglis BM, Lewis JS. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. J Vis Exp. 2015;96.","DOI":"10.3791\/52521"},{"issue":"1","key":"5097_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2967\/jnumed.117.194555","volume":"59","author":"JA O'Donoghue","year":"2018","unstructured":"O'Donoghue JA, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for (89)Zr-trastuzumab in patients with esophagogastric cancer. J Nucl Med. 2018;59(1):161\u20136.","journal-title":"J Nucl Med"},{"issue":"6","key":"5097_CR38","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","volume":"18","author":"R Laforest","year":"2016","unstructured":"Laforest R, et al. [(89)Zr]Trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer. Mol Imaging Biol. 2016;18(6):952\u20139.","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"5097_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","volume":"12","author":"M Tabrizi","year":"2010","unstructured":"Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010;12(1):33\u201343.","journal-title":"AAPS J"},{"key":"5097_CR40","doi-asserted-by":"crossref","unstructured":"Terwisscha van Scheltinga, A.G., et al., Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative 89Zr-immunoPET. Mol Cancer Ther, 2017. 16(1): p. 134\u2013142.","DOI":"10.1158\/1535-7163.MCT-16-0449"},{"issue":"9","key":"5097_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"5097_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","volume":"122","author":"J Kim","year":"2007","unstructured":"Kim J, et al. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122(2):146\u201355.","journal-title":"Clin Immunol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05097-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05097-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05097-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T07:51:19Z","timestamp":1723881079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05097-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5097"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05097-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Anchal Ghai has no conflict of interest.Alexander Zheleznyak has no conflict of interest.Matt Mixdorf has no conflict of interest.Julie O\u2019Neal has no conflict of interest.Julie Ritchey has no conflict of interest.Michael Rettig has no conflict of interest.John DiPersio received research support from Bioline, Rodger and Paula Riney Foundation (gift), and grant from NIH\/NCI: U54CA199092 (PI: Achilefu, Project 3 Leader: Di Persio).Monica Shokeen is supported by grants from NIH\/NCI: R01 CA248493\u00a0and U54CA199092.Samuel Achilefu is supported by grants from the National Institutes of Health (U54 CA199092, R01 EB021048), NIH Shared Instrumentation Grants S10 OD020129, S10 OD025264, S10 OD027042\u00a0and Department of Defense CDMRP BCRP W81XWH1610286.No other potential conflict of interest relevant to this article was reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable institutional guidelines for the care and use of animals were followed. All the animal studies were performed at Washington University School of Medicine under the guide for the Care and Use of Laboratory animals. This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}